
pmid: 28278730
Brentuximab vedotin (BV), an antibody–drug conjugate that selectively delivers MMAE into CD30-expressing cells, has shown high response rates in both relapsed/refractory Hodgkin lymphoma (HL) and a...
Brentuximab Vedotin, Immunoconjugates, Humans, Ki-1 Antigen, Antineoplastic Agents, Hodgkin Disease, Biomarkers
Brentuximab Vedotin, Immunoconjugates, Humans, Ki-1 Antigen, Antineoplastic Agents, Hodgkin Disease, Biomarkers
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
